image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

Incubation of <i>T</i>. <i>brucei</i> with Pol I transcription inhibitors results in a dramatic decrease in VEX1 foci. by Louise E. Kerry (3815164)

S1 Data - by Win Win Pyone (20396432)

“…Diuron exhibits higher phytotoxicity in sand compared to loamy sand, with ED₅₀ values (which is the dose at which diuron causes a 50% decrease in plant growth) of 0.03 mg kg^-1 and 0.07 mg kg^-1 for canola shoot biomass inhibition and 0.01 mg kg^-1 and 0.06 mg kg^-1 for root dry weight reduction, respectively. …”

Effect of cilostazol on the serum ALT (A), AST (B) levels in rats with TAA-induced liver fibrosis. by Sally A. El Awdan (710176)

Effect of cilostazol on liver α-SMA (A) and COL-1 (B) in TAA-induced fibrosis in rats. by Sally A. El Awdan (710176)

Fig 1 - by Win Win Pyone (20396432)

Decreased neutrophil and monocyte antigen expression in the paws of anti-S100A9-treated mice. by Annabelle Cesaro (112070)

Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

“…</p>Conclusion<p>Concomitant epidural anesthesia reduced by 15% the EC₅₀ of predicted Ce_prop for LOC, decreased the consumptions of propofol and remifentanil during maintenance of anesthesia, and fastened recovery from anesthesia.…”

Salience of authority-virtue phrases by year. by Daniel Hart (440152)

Dexmedetomidine in combination with morphine improves postoperative analgesia and sleep quality in elderly patients after open abdominal surgery: A pilot randomized control trial by Huai-Jin Li (5628722)

“…</p><p>Results</p><p>The 72-hour morphine consumption was lower in the DEX group than in the CTRL group (median 39.0 mg [interquartile range 37.3, 41.0] in the DEX group vs. 49.0 mg [45.5, 50.0] in the CTRL group; median difference -9.0 mg [95% CI -10.0, -6.0], P < 0.001). …”

XRD diffraction pattern spectra of PFAgNPs. by Kenedy Kiyimba (9942393)

“…The no observed adverse effect level was 50 mg/kgBW, the lowest observed adverse effect level was 100 mg/kgBW, and median lethal dose (LD₅₀) was 1000 mg/kg. …”

Mean percentage changes (95% CI) in total testosterone, SHBG and free testosterone (mITT analysis). by Chanel Avenant (409756)

Subjects:

Pairwise comparisons of hormonal results for DMPA-IM vs NET-EN expressed as mean percentage differences (95% CI) (mITT analysis). by Chanel Avenant (409756)

Subjects:

Total testosterone (nmol/L), SHBG (nmol/L) and free testosterone (pmol/L) outcomes at baseline and 25 weeks (mITT analysis). by Chanel Avenant (409756)

Subjects:

Total testosterone (nmol/L), SHBG (nmol/L) and free testosterone (nmol/L), outcomes at baseline and 25 weeks (mITT analysis). by Chanel Avenant (409756)

Subjects:

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”